<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432663</url>
  </required_header>
  <id_info>
    <org_study_id>2017-LS002</org_study_id>
    <nct_id>NCT03432663</nct_id>
  </id_info>
  <brief_title>Time-dependent Amiodarone Treatment in Atrial Fibrillation</brief_title>
  <official_title>Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sixty consecutive emergency patients with newly diagnosed Atrial Fibrillation were randomized
      into two groups. The first received intravenous amiodarone infusions continuously for 24
      hours; the second received Amiodarone until sinus rhythms was reached or for up to 72 hours.

      The efficacy and safety of administering intravenous infusions of amiodarone for up to 72
      hours were investigated and compared to the efficacy and safety of administering a standard
      24 hours infusion of amiodarone. Specifically, the use of up to 72 hours infusions was
      considered as a new strategy to improve rates of conversion to sinus rhythm without altering
      the safety profile of the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open randomized clinical trial was conducted that included 60 emergency adult patients who
      were candidates for drug cardioversion after first symptomatic episodes of AF.

      The patients were randomized in equal proportions and sequentially placed in one of two
      treatment groups; no patient knew to which group he or she belonged. The first group received
      intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg
      until 24 hours was reached. The second group received intravenous amiodarone infusions at
      doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 hours for up to 72 hours.

      All patients were continuously monitored using electrocardiograms, and echocardiograms were
      performed within 24 hours after the randomized trial began. The exact time of each patient's
      cardioversion was documented. In addition, general laboratory tests, lipid profiles, thyroid
      profiles and chest X-rays were obtained for all patients.

      A sample size of 30 subjects in each group was calculated. A conversion rate of 60% was
      assumed, according to literature, and an estimated increase to 90% was assumed for the
      experimental group to find differences with a power of 0.8 and an alpha error of 0.05.

      The primary goal was to obtain was a sinus rhythm conversion rate. The secondary goal was to
      obtain a combined complication rate by noting various complications in the patients, such as
      phlebitis, symptomatic hypotension that required vasopressors, bradycardia, nausea, vomiting
      and any organ embolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2008</start_date>
  <completion_date type="Actual">November 30, 2009</completion_date>
  <primary_completion_date type="Actual">November 30, 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>60 emergency adult patients who were candidates for drug cardioversion after first symptomatic episodes of Atrial fibrillation to either (1)24 hour continuous infusion or (2)72 hours continuous intravenous Amiodarone or until sinus rhythms was reached.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obtain a continuous sinus rhythm</measure>
    <time_frame>72 hours</time_frame>
    <description>Monitoring using continuous telemetry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rate of continuous amiodarone intravenous infusion</measure>
    <time_frame>72 hours</time_frame>
    <description>Obtain a combined complication rate by noting various complications in the patients, such as phlebitis, symptomatic hypotension that required vasopressors, bradycardia, nausea, vomiting and any organ embolism.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>24h infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>72h infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous amiodarone(1)</intervention_name>
    <description>Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached</description>
    <arm_group_label>24h infusion</arm_group_label>
    <other_name>24 hour amiodarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous amiodarone(2)</intervention_name>
    <description>Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached</description>
    <arm_group_label>72h infusion</arm_group_label>
    <other_name>72 hour amiodarone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years old

          -  Emergency patients

          -  First symptomatic episodes of Atrial Fibrillation

        Exclusion Criteria:

          -  Hemodynamic instability,

          -  Previous use of antiarrhythmic drugs

          -  Use of digoxin seven or fewer days prior to the study

          -  Active thyroid disease

          -  Known adverse reactions to amiodarone

          -  Other ventricular arrhythmias

          -  Contraindications for anticoagulation

          -  Acute renal failure

          -  Chronic liver disease

          -  Transaminase levels that were twice the normal levels

          -  Acute pulmonary edema

          -  Uncontrolled hypertension (&gt; 180/110 mmHg)

          -  Unstable angina

          -  Patients who were pregnant and/or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis A Sanchez-Trujillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Escuela de Medicina y Ciencias de la Salud. Tecnológico de Monterrey. Monterrey. México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. José Eleuterio González&quot;. Universidad Autónoma de Nuevo León</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M, Litinski I, Simantov R, Moshkovitz Y, Zaidenstein R, Peleg E, Vered Z, Golik A. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J. 1999 Dec;20(24):1833-42.</citation>
    <PMID>10581142</PMID>
  </reference>
  <reference>
    <citation>Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, Michl K, Owens DK, Susman J, Allen DI, Mottur-Pilson C; AAFP Panel on Atrial Fibrillation; ACP Panel on Atrial Fibrillation. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003 Dec 16;139(12):1009-17.</citation>
    <PMID>14678921</PMID>
  </reference>
  <reference>
    <citation>Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med. 2000 Jul;36(1):1-9.</citation>
    <PMID>10874228</PMID>
  </reference>
  <reference>
    <citation>Tuseth V, Jaatun HJ, Dickstein K. Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment. Heart. 2005 Jul;91(7):964-5.</citation>
    <PMID>15958375</PMID>
  </reference>
  <reference>
    <citation>Waldo AL. Management of atrial fibrillation: the need for AFFIRMative action. AFFIRM investigators. Atrial Fibrillation Follow-up Investigation of Rhythm Management. Am J Cardiol. 1999 Sep 15;84(6):698-700.</citation>
    <PMID>10498142</PMID>
  </reference>
  <reference>
    <citation>Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1825-33.</citation>
    <PMID>12466506</PMID>
  </reference>
  <reference>
    <citation>Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.</citation>
    <PMID>11343485</PMID>
  </reference>
  <reference>
    <citation>Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998 Sep 8;98(10):946-52.</citation>
    <PMID>9737513</PMID>
  </reference>
  <reference>
    <citation>Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 1994 Feb;89(2):724-30.</citation>
    <PMID>8313561</PMID>
  </reference>
  <reference>
    <citation>Kumana CR, Cheung BM, Cheung GT, Ovedal T, Pederson B, Lauder IJ. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. Br J Clin Pharmacol. 2005 Oct;60(4):347-54. Review.</citation>
    <PMID>16187966</PMID>
  </reference>
  <reference>
    <citation>Lim HS, Hamaad A, Lip GY. Clinical review: clinical management of atrial fibrillation - rate control versus rhythm control. Crit Care. 2004 Aug;8(4):271-9. Epub 2004 Feb 19. Review.</citation>
    <PMID>15312210</PMID>
  </reference>
  <reference>
    <citation>Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2003 Jan 15;41(2):255-62.</citation>
    <PMID>12535819</PMID>
  </reference>
  <reference>
    <citation>Hauser TH, Pinto DS, Josephson ME, Zimetbaum P. Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 2004 May 1;93(9):1173-6.</citation>
    <PMID>15110217</PMID>
  </reference>
  <reference>
    <citation>Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003 Jun;89(2-3):239-48. Review.</citation>
    <PMID>12767548</PMID>
  </reference>
  <reference>
    <citation>Hagens VE, Van Gelder IC, Crijns HJ; RAte Control Versus Electrical Cardioversion Of Persistent Atrial Fibrillation (RACE) Study Group. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. Card Electrophysiol Rev. 2003 Jun;7(2):118-21. Review.</citation>
    <PMID>14618033</PMID>
  </reference>
  <reference>
    <citation>McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003 Dec 16;139(12):1018-33. Review.</citation>
    <PMID>14678922</PMID>
  </reference>
  <reference>
    <citation>Maisel WH, Kuntz KM, Reimold SC, Lee TH, Antman EM, Friedman PL, Stevenson WG. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997 Aug 15;127(4):281-4.</citation>
    <PMID>9265427</PMID>
  </reference>
  <reference>
    <citation>Kreiss Y, Sidi Y, Gur H. Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department. Postgrad Med J. 1999 May;75(883):278-81.</citation>
    <PMID>10533631</PMID>
  </reference>
  <reference>
    <citation>Xanthos T, Bassiakou E, Vlachos IS, Bassiakos S, Michalakis K, Moutzouris DA, Papadimitriou L. Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. Int J Cardiol. 2007 Oct 18;121(3):291-5. Epub 2007 Apr 16.</citation>
    <PMID>17434635</PMID>
  </reference>
  <reference>
    <citation>Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000 Jun;117(6):1538-45.</citation>
    <PMID>10858380</PMID>
  </reference>
  <reference>
    <citation>Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000 Nov 25;356(9244):1789-94.</citation>
    <PMID>11117910</PMID>
  </reference>
  <reference>
    <citation>Bernard EO, Schmid ER, Schmidlin D, Scharf C, Candinas R, Germann R. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med. 2003 Apr;31(4):1031-4.</citation>
    <PMID>12682468</PMID>
  </reference>
  <reference>
    <citation>Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, Cooper MJ. Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am Heart J. 2004 Jan;147(1):E3.</citation>
    <PMID>14691441</PMID>
  </reference>
  <reference>
    <citation>Decker WW, Smars PA, Vaidyanathan L, Goyal DG, Boie ET, Stead LG, Packer DL, Meloy TD, Boggust AJ, Haro LH, Laudon DA, Lobl JK, Sadosty AT, Schears RM, Schiebel NE, Hodge DO, Shen WK. A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation. Ann Emerg Med. 2008 Oct;52(4):322-8. doi: 10.1016/j.annemergmed.2007.12.015. Epub 2008 Mar 14.</citation>
    <PMID>18339449</PMID>
  </reference>
  <reference>
    <citation>del Arco C, Martín A, Laguna P, Gargantilla P; Investigators in the Spanish Atrial Fibrillation in Emergency Medicine Study Group (GEFAUR). Analysis of current management of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med. 2005 Nov;46(5):424-30. Epub 2005 May 31.</citation>
    <PMID>16271674</PMID>
  </reference>
  <reference>
    <citation>Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003 May 21;41(10):1690-6.</citation>
    <PMID>12767648</PMID>
  </reference>
  <reference>
    <citation>Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 Jun 19;358(25):2667-77. doi: 10.1056/NEJMoa0708789.</citation>
    <PMID>18565859</PMID>
  </reference>
  <reference>
    <citation>Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, García-Dorado D, Soler-Soler J. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996 Apr;27(5):1079-82.</citation>
    <PMID>8609324</PMID>
  </reference>
  <reference>
    <citation>Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8.</citation>
    <PMID>1866765</PMID>
  </reference>
  <reference>
    <citation>Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández-Gómez JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000 Nov 1;86(9):950-3.</citation>
    <PMID>11053705</PMID>
  </reference>
  <reference>
    <citation>Kochiadakis GE, Igoumenidis NE, Hamilos ME, Marketou ME, Chlouverakis GI, Vardas PE. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007 Jun 15;99(12):1721-5. Epub 2007 Apr 26.</citation>
    <PMID>17560882</PMID>
  </reference>
  <reference>
    <citation>Cybulski J, Kułakowski P, Budaj A, Danielewicz H, Maciejewicz J, Kawka-Urbanek T, Ceremuzyński L. Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation. Clin Cardiol. 2003 Jul;26(7):329-35.</citation>
    <PMID>12862299</PMID>
  </reference>
  <reference>
    <citation>Hilleman DE, Spinler SA. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy. 2002 Jan;22(1):66-74.</citation>
    <PMID>11794432</PMID>
  </reference>
  <reference>
    <citation>National Clinical Guideline Centre (UK). Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Care Excellence (UK); 2014 Jun.</citation>
    <PMID>25340239</PMID>
  </reference>
  <reference>
    <citation>January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28. Erratum in: Circulation. 2014 Dec 2;130(23):e272-4.</citation>
    <PMID>24682347</PMID>
  </reference>
  <reference>
    <citation>Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011 Mar;13(3):329-45. doi: 10.1093/europace/euq450. Epub 2011 Jan 11.</citation>
    <PMID>21227948</PMID>
  </reference>
  <reference>
    <citation>Nadarasa K, Williams MJ. Single high oral dose amiodarone for cardioversion of recent onset atrial fibrillation. Heart Lung Circ. 2012 Aug;21(8):444-8. doi: 10.1016/j.hlc.2012.03.015. Epub 2012 May 2.</citation>
    <PMID>22554874</PMID>
  </reference>
  <reference>
    <citation>Patel DA, Lavie CJ, Milani RV, Shah S, Gilliland Y. Clinical implications of left atrial enlargement: a review. Ochsner J. 2009 Winter;9(4):191-6.</citation>
    <PMID>21603443</PMID>
  </reference>
  <reference>
    <citation>Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998 Mar 1;31(3):588-92.</citation>
    <PMID>9502640</PMID>
  </reference>
  <reference>
    <citation>Emren SV, Kocabaş U, Duygu H, Levent F, Şimşek EÇ, Yapan Emren Z, Tülüce S. The role of HATCH score in predicting the success rate of sinus rhythm following electrical cardioversion of atrial fibrillation. Kardiol Pol. 2016;74(9):978-84. doi: 10.5603/KP.a2016.0044. Epub 2016 Apr 4.</citation>
    <PMID>27040017</PMID>
  </reference>
  <reference>
    <citation>Suenari K, Chao TF, Liu CJ, Kihara Y, Chen TJ, Chen SA. Usefulness of HATCH score in the prediction of new-onset atrial fibrillation for Asians. Medicine (Baltimore). 2017 Jan;96(1):e5597. doi: 10.1097/MD.0000000000005597.</citation>
    <PMID>28072697</PMID>
  </reference>
  <reference>
    <citation>Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006 Sep;8(9):651-745. Erratum in: Europace. 2007 Sep;9(9):856.</citation>
    <PMID>16987906</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Intravenous Amiodarone</keyword>
  <keyword>Drug safety profile</keyword>
  <keyword>Chemical cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

